Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

4 Large-Cap Medical Device Stocks to Buy Amid Political Woes

Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.

    Mazor Robotics Hits 52-Week High Through Medtronic Alliance

    Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.

      GNC Holdings Gains on New GNC Strength Amid Soft Revenues

      GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.

        3 MedTech Stocks Set to Rally in the Second Half

        The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.

          Haemonetics Grows on Strong Plasma, Blood Center Sluggish

          Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.

            Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

            Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

              The Cooper Companies (COO) Beats Earnings Estimates in Q3

              The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.

                Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm

                Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.

                  Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

                  Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

                    BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                    BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                      Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates

                      Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.

                        VWR Awaits Merger Closure, Stock Upside Potential Limited

                        VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.

                          Cooper (COO) Poised to Grow on Specialty Lenses Prospects

                          Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.

                            Thermo Fisher Acquires Patheon, Boosts Laboratory Products

                            Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.

                              Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now

                              Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.

                                Intuitive Surgical (ISRG) Well Poised on Procedural Business

                                Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.

                                  LabCorp Grows on Solid Diagnostics, Currency Woes a Drag

                                  Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.

                                    Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well

                                    Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.

                                      PetMed Express Focuses on Advertising, Competition Rife

                                      PetMed Express (PETS) focuses on advertising to boost new order sales is striving to implement several strategies to revitalize its top line.

                                        Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm

                                        Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.

                                          LabCorp & Interpace Extend Deal, Boost Cancer Portfolio

                                          LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.

                                            NxStage System One Gets FDA Nod for Solo Home Hemodialysis

                                            The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.

                                              Veeva (VEEV) to Gain Through Subscription Revenue Focus

                                              Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.

                                                Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

                                                Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

                                                  LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

                                                  The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.